Edwards Lifesciences Corp (EW) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Total Revenue Chart for Edwards Lifesciences Corp
Edwards Lifesciences Corp (EW) revenue for FY2025 was USD 6.1B, a 11.5% change from FY2024. Edwards Lifesciences Corp's revenue grew from USD 905.0M in 1999 to USD 6.1B in 2025 (570.5% over 26 years). Earnings per share grew from USD 0.08 in 2002 to USD 1.83 in 2025 (2320.1%). Revenue compound annual growth rate: 5-year CAGR of 6.7%, 10-year CAGR of 9.3%, 20-year CAGR of 9.4%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $51.43B
- Implied Share Price
- $89.32
- Enterprise Value
- $48.04B
- Revenue (TTM)
- $6.51B
- EBITDA
- $2.00B
- Profit Margin
- 15.43%
- Trailing P/E
- 53.17
- Forward P/E
- 29.85
- Price/Book (MRQ)
- 4.86
- Price/Sales (TTM)
- 7.91
- EV/EBITDA
- 29.08
- EV/Revenue
- 7.38
- Dividend Yield
- —
- Book Value
- $17.90
- Free Cash Flow (FY2025)
- $1.33B
- Free Cash Flow Yield
- 2.60%
Snapshot as of 6th August 2026 — not point-in-time controlled, may lag the live market by a few days.